Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease
Trial details
- Registry ID
- NCT05099770
- Drugs studied
- Renal Autologous Cell Therapy (REACT/ rilparencel), Sham Comparator
TrialRedline tracks 4 clinical trials sponsored by Prokidney: 1 Phase 3, 3 Phase 2.
Company identity has not yet been verified
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney DiseaseNCT05099770 | Renal Autologous Cell Therapy (REACT/ rilparencel), Sham Comparator | Active not recruiting | 2029-12Estimated |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Renal Autologous Cell Therapy (REACT) in Subjects With Type 1 or 2 Diabetes and Chronic Kidney Disease (REGEN-007)NCT05018416 | Renal Autologous Cell Therapy (REACT) | Completed | 2025-05-20Actual |
| A Study of Renal Autologous Cell Therapy (REACT) in Type 2 Diabetics With Chronic Kidney DiseaseNCT02836574 | Renal Autologous Cell Therapy (REACT), Renal Biopsy | Completed | 2023-12Actual |
| A Study of Autologous Renal Autologous Cell Therapy (REACT) in Patients With Diabetic Chronic Kidney DiseaseNCT03270956 | Renal Autologous Cell Therapy (REACT) | Completed | 2022-11-17Actual |
Names as written in the registry records.
Before: Recruiting. After: Active not recruiting.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Clinical Endpoint. After: Measure: Surrogate / Intermediate Efficacy Endpoint -eGFR Slope Measure: Clinical Endpoint.
Before: Feb 2027. After: Dec 2029.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Primary Composite Endpoint. After: Measure: Clinical Endpoint.